
Understand how testosterone, LH and FSH relate to sperm production, why blood tests are not fertility tests and how testosterone therapy affects signalling.

Testosterone is an androgen, a hormone involved in male reproductive function. Sperm production is a separate process that depends on coordinated hormonal signals within the testes. Fertility depends on sperm production and other reproductive factors. These systems are connected, but a testosterone result and a fertility assessment describe different outcomes.
The European Association of Urology (EAU) makes this distinction in its guidance. It separates testosterone treatment for symptomatic hypogonadism from treatment intended to address male infertility. Understanding how hormones fit into reproductive function helps explain why those treatment goals require different evaluations.
This article is for informational purposes only and is not medical advice. A qualified clinician should interpret hormone results and fertility concerns alongside your medical and reproductive history. Do not start, stop or alter prescribed testosterone or other hormone treatment based on this article.
A hormone reference-range label is not a fertility verdict. The clinically useful distinction is whether testosterone is low and whether related signals are high, low or inappropriately normal. These patterns help a clinician investigate the hormonal system rather than treating one result as a complete answer.
The EAU distinguishes primary from secondary hypogonadism using this broader context. LH means luteinizing hormone. FSH means follicle-stimulating hormone. Together they are called gonadotropins, signals involved in testicular function.
The EAU describes secondary hypogonadism as involving low or inappropriately normal gonadotropin levels. The word inappropriately matters: a result labelled normal may not represent an appropriate response to the rest of the hormonal picture.
This is why reading only the laboratory's normal label can miss the clinical question. The clinician needs to assess how the hormone results relate to one another and to the suspected diagnosis.
In men with testicular deficiency, the EAU says LH and FSH are usually high. This can occur with or without low testosterone. A testosterone result therefore does not capture every relevant aspect of testicular function.
These are qualitative diagnostic patterns, not numerical fertility targets. A normal testosterone result does not establish normal sperm production. The EAU treats hormonal evaluation and semen analysis as distinct parts of an infertility assessment.
FSH contributes useful information, but the EAU cautions against treating it as a definitive prediction of sperm retrieval. In certain surgical sperm-retrieval settings, FSH does not accurately predict whether sperm production will be found.
The practical implication is specific: a high FSH result should not be translated into a personal conclusion that sperm cannot be found. That question requires specialist interpretation in the relevant clinical setting.
An adult man may seek care because of symptoms attributed to low testosterone, a fertility concern or both. These starting points deserve assessment, but they should not be treated as interchangeable diagnoses.
The EAU recommends testosterone therapy for symptomatic hypogonadal men who are not considering parenthood. It recommends against using testosterone therapy to treat male infertility. That distinction separates assessment of androgen-related symptoms from assessment of reproductive function.
When sperm production is being investigated, the clinical findings may include oligozoospermia or azoospermia. These terms describe low sperm numbers or an absence of sperm detected in semen. The EAU recommends total testosterone plus LH and FSH assessment in these settings.
Neither finding automatically establishes low testosterone as the cause. Instead, the semen finding creates a reason to investigate the hormonal picture alongside other aspects of reproductive health.
The EAU's focused infertility evaluation includes:
Additional investigations depend on clinical features and semen findings. This approach gives each part of the assessment a defined purpose rather than expecting symptoms or a single blood result to answer every question.
For the patient, the useful distinction is between describing a concern and establishing its cause. A discussion about symptoms belongs in the medical history. A question about sperm production requires an assessment that addresses semen as well as the relevant hormonal signals.
The EAU guidance identifies several important influences: coordinated gonadotropin activity, the underlying site of hormonal dysfunction and exposure to external testosterone. These affect different parts of the reproductive system and should not be combined into one general claim about raising testosterone.
LH-related signalling supports testosterone production within the testes. The EAU illustrates this through its discussion of hCG, which acts like LH. In men with hypopituitarism after puberty, hCG can stimulate intratesticular testosterone production and spermatogenesis.
Intratesticular means within the testes. Spermatogenesis means sperm production. These terms identify the local reproductive process rather than just the testosterone concentration measured in blood.
FSH has a distinct role. The EAU describes it as promoting spermatogenesis and testicular growth during puberty. Its adult fertility guidance also includes FSH in diagnosis-specific treatment for secondary hypogonadism.
The key biological point is coordination. Testosterone production within the testes and the signals supporting sperm production belong to a connected system. LH and FSH are therefore not redundant measurements, even though both may appear on the same hormone panel.
The EAU describes fertility-focused treatment with hCG and FSH for adults with secondary hypogonadism. Its recommendations address men with congenital or acquired hypogonadotropic hypogonadism who wish to conceive.
That is a diagnosis-specific recommendation. It does not establish these medicines as a general substitute for testosterone therapy in every man with low testosterone or impaired fertility.
The distinction between primary and secondary hypogonadism therefore has practical importance. It helps explain why two men with a low testosterone result may require different investigations and different discussions about reproductive goals.
The EAU also describes semen analysis as part of assessing response to fertility-directed treatment. This keeps the evaluation tied to the reproductive outcome being pursued rather than judging success only through a blood testosterone result.
External testosterone means testosterone supplied as treatment rather than produced by the body's own system. According to the EAU male-hypogonadism guideline, testosterone therapy inhibits pituitary gonadotropin secretion. This can impair spermatogenesis and sperm-cell maturation.
The guideline also states that testosterone therapy suppresses endogenous testosterone secretion. Endogenous means produced within the body. Raising testosterone through treatment is therefore not equivalent to preserving the body's own reproductive signalling.
This explains the apparent contradiction: testosterone is involved in male reproduction, yet testosterone therapy can work against sperm production. The relevant issue is not simply whether testosterone is present. It is how treatment affects the signals that support production within the testes.
The EAU strongly recommends against testosterone therapy for male infertility or for men wishing to become fathers. The fertility trade-off associated with testosterone treatment should therefore be part of the discussion before treatment when parenthood matters.
This guidance establishes a fertility risk, not an individual prediction. It does not mean every man using testosterone becomes infertile or that any impairment is necessarily permanent. The cited guidance does not establish an individual's sperm count, chance of conception or recovery timeline.
A man considering testosterone treatment should tell the clinician whether he wants children now or may want them later. For someone already receiving treatment, that discussion belongs with the treating clinician rather than becoming a reason to change medication independently.
The useful next step is to clarify the treatment goal and diagnosis. Improving androgen-related symptoms and supporting sperm production are different outcomes. A clinical plan needs to acknowledge both when both matter.
Ask your physician: “How do my testosterone, LH and FSH results fit the suspected diagnosis? Do my fertility goals warrant semen analysis? How would the proposed treatment affect sperm production?”
Blood testosterone and sperm production answer different questions, which is why Testostra explains their relationship without presenting a lab result as a diagnosis. Its coverage of hormone testing and reproductive health gives men clearer context for discussing testosterone, LH and FSH with a qualified clinician.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra